Question from Deputy Ken O'Flynn - PQ 15815-26
Deputy O'Flynn asked about the full health technology assessment of tirzepatide for type 2 diabetes. Read the HSE response.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy O'Flynn asked about the full health technology assessment of tirzepatide for type 2 diabetes. Read the HSE response.
Deputy Cullinane asked about the funding allocated to developing a new adult mental health unit at UHW. Read the HSE response.
Deputy O'Flynn asked about the approval of a dataset or outcome monitoring system for gender identity services for children and young people.
Deputy O'Flynn asked about any evaluations of the Public Only Consultant Contract since its introduction. Read the HSE response.
Deputy O'Flynn asked about the health technology assessments conducted in respect of tirzepatide. Read the HSE response.
Deputy O'Flynn asked about the gender-related healthcare services for children and adolescents. Read the HSE response.
Deputy O'Flynn asked about the average waiting time and the longest waiting time for a first outpatient appointment in a publicly funded chronic pain service.
Deputy O'Flynn asked about the budget impact analysis in respect of the proposed reimbursement of tirzepatide and semaglutide for diabetes and weight management
Deputy O'Flynn asked for the number of minors referred from Ireland to NHS gender identity services under the Treatment Abroad Scheme from 2023 to 2026.